Renormalizable acausal theories of classical gravity coupled with interacting quantum fields

We prove the renormalizability of various theories of classical gravity coupled with interacting quantum fields. The models contain vertices with dimensionality greater than four, a finite number of matter operators and a finite or reduced number of independent couplings. An interesting class of models is obtained from ordinary power-counting renormalizable theories, letting the couplings depend on the scalar curvature R of spacetime. The divergences are removed without introducing higher-derivative kinetic terms in the gravitational sector. The metric tensor has a non-trivial running, even if it is not quantized. The results are proved applying a certain map that converts classical instabilities, due to higher derivatives, into classical violations of causality, whose effects become observable at sufficiently high energies. We study acausal Einstein-Yang-Mills theory with an R-dependent gauge coupling in detail. We derive all-order formulas for the beta functions of the dimensionality-six gravitational vertices induced by renormalization. Such beta functions are related to the trace-anomaly coefficients of the matter subsector.Comment: 36 pages; v2: CQG proof-corrected versio

The Effect of Nigella sativa on Infections and Inflammation: A Narrative Review with Focus on Helicobacter pylori

Nigella sativa, known as black seed, is traditionally utilized in Middle Eastern and Asian medicine for millennia as a therapeutic herb. Preclinical and clinical research have shown that thymoquinone, its active ingredient, has immunomodulatory, antioxidant, anti-inflammatory, and antibacterial effects. The aim of this narrative review is to highlight present knowledge on the function of Nigella sativa in treating infections, especially Helicobacter pylori, and its regulatory effects on inflammatory processes. To emphasize the therapeutic potential of Nigella sativa as an adjuvant in infectious and inflammatory illnesses, the review gathers results from systematic reviews, in vitro and in vivo research, and clinical trials

Surface-selective direct 17^{17}O DNP NMR of CeO2_{2} nanoparticles

Surface-selective direct $^{17}$O DNP has been demonstrated for the first time on CeO$_{2}$ nanoparticles, for which the first three layers can be distinguished with high selectivity. Polarisation build-up curves show that the polarisation of the (sub-)surface sites builds up faster than the bulk, accounting for the remarkable surface selectivity.We are grateful for financial support by the Oppenheimer Foundation (M. A. H.), the Cambridge Commonwealth Trusts (D. M. H.), the National Natural Science Foundation of China (NSFC) (21573103 and 21661130149) and the Royal Society Newton Fund (L. P.). The DNP experiments were performed at the DNP MAS NMR Facility at the University of Nottingham, with thanks to the EPSRC for funding of pilot studies (EP/L022524/1)

Lancet

BACKGROUND: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. METHODS: CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). INTERPRETATION: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. FUNDING: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation

Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3)

Background: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. Methods: We analyzed individual data for adults (15–99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000–2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. Results: The study included 556,237 adults. In 2010–2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%–38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000–2004 and 2005–2009. These improvements were more noticeable among adults diagnosed aged 40–70 years than among younger adults. Conclusions: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines